Navigation Links
BioMarin Announces Buy Back of Naglazyme Royalties From Adelaide Health Authority
Date:11/30/2011

NOVATO, Calif., Nov. 30, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has completed the buy back of certain intellectual property from SA Pathology, a unit of the Central Adelaide Local Health Network located in Adelaide, Australia for an upfront payment of $81 million.  The intellectual property includes patents related to the purified form of Naglazyme and the method of using the enzyme in the treatment of MPS VI, which expire between 2022 and 2023.  Prior to this transaction, BioMarin licensed this intellectual property from SA Pathology and paid a five percent royalty on net sales of Naglazyme. 

"We are pleased to complete this transaction as we are confident in the future sales potential of Naglazyme.  We continue to expand the product into new geographies and expect steady growth for years to come.  We do not see any competition on the horizon due to the extremely small patient population, the complexity and expense of manufacturing the product and the intellectual property covered by the patents," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin.  "The transaction will allow BioMarin to generate approximately $10 to $15 million in cash per year with no incremental operating costs.  This deal makes sense for BioMarin because we see continued growth in the global Naglazyme business."

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which B
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA
2. BioMarin Announces FDA Approval of Expanded Biologics Manufacturing Facility
3. BioMarin to Host a Research and Development Day on December 8th
4. BioMarin Announces Third Quarter 2011 Financial Results
5. BioMarin to Present at the UBS Global Life Sciences Conference
6. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
7. BioMarin to Present at the Baird Health Care Conference
8. BioMarin to Present at the Wedbush Life Sciences Conference
9. BioMarin Announces Second Quarter 2011 Financial Results
10. BioMarin to Host Second Quarter 2011 Financial Results Conference Call and Webcast on Thursday, July 28 at 5:00 p.m. ET
11. BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 5, 2015  Kewaunee Scientific Corporation (NASDAQ: ... Gehl to Kewaunee Scientific,s Board of Directors, effective April ... Concord, North Carolina . The election of ... notification to the Board of his intention to resign ... increased professional commitments. Upon his election, Mr. Gehl was also ...
(Date:5/5/2015)... 5, 2015 Faced with fast economy and population ... China,s medical device industry has been ... largest demands have been Beijing , ... other first-tier cities. However, the entry of a large number ... "high-end" markets in first-tier cities increasingly saturated. How do medical ...
(Date:5/5/2015)... , May 5, 2015  As cannabis prohibition ends one state at a time, more cannabis entrepreneurs are coming up with ... phase, and the primary reason is lack of funding. ... ... ... ...
Breaking Medicine Technology:Keith M. Gehl Elected to Kewaunee Scientific Board of Directors 2Keith M. Gehl Elected to Kewaunee Scientific Board of Directors 3MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets 2MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets 3MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets 4Top Ten Ways Cannabis Startups are Getting Funded 2Top Ten Ways Cannabis Startups are Getting Funded 3Top Ten Ways Cannabis Startups are Getting Funded 4
... a study sponsored by Topaz Pharmaceuticals Inc., a privately ... Massachusetts, Amherst presented data showing that a 0.5% ivermectin ... permethrin resistant head lice.  The data were presented in ... the 37th Annual Meeting of the Society for ...
... Lechleiter, Ph.D., chairman, president and chief executive officer of ... today urged that biopharmaceuticals be included in transatlantic trade ... on Germany,s conference on "The Transatlantic Partnership in the ... State Secretary in the Federal Finance Ministry Jorg Asmussen; ...
Cached Medicine Technology:Topaz Pharmaceuticals' Ivermectin Cream In Vitro Data Demonstrates Activity Against Head Lice Eggs 2Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions 2
(Date:5/5/2015)... 2015 B. E. Smith, the only ... has been retained to recruit a new administrator ... top executive search firm in the healthcare industry, B. ... executives into organizations. , Shodair Children’s Hospital is the ... to offer both acute and residential inpatient services, as ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 The PracticeMatch ... from 5:00 to 8:00 pm at the Rochester Marriott, 1001 ... clinics and groups with career opportunities will be attending from ... enjoy free hors d’oeuvres and raffle prize drawings. , Leslie ... “Rochester is an ideal location to hold a career fair. ...
(Date:5/5/2015)... Atlantic Information Services, Inc. (AIS), publisher ... Plans, and other industry-leading health care business publications, ... AIS’s Value-Based Care News. Written for health plans, ... and their advisers, AIS’s Value-Based Care News covers ... coordinated care, global payments and other innovative arrangements ...
(Date:5/5/2015)... May 05, 2015 The ... 2014” provides comparative analysis on the therapeutic ... R&D pipelines by identifying new targets and ... Complete report is available at http://www.rnrmarketresearch.com/liver-fibrosis-pipeline-review-h2-2014-market-report.html ... Liver Fibrosis – Pipeline Review, H2 2014 ...
(Date:5/5/2015)... GREEN, Ohio (PRWEB) May 05, 2015 ... of ergonomic seating solutions, will feature models from its ... 17, at the Merchandise Mart in Chicago. Headlining the ... chairs from the MVMT™ seating line, as well as ... by BioFit™ Collection. Additionally, BioFit president Ed Metzger will ...
Breaking Medicine News(10 mins):Health News:Shodair Children’s Hospital Retains B. E. Smith to Recruit New Administrator 2Health News:Shodair Children’s Hospital Retains B. E. Smith to Recruit New Administrator 3Health News:PracticeMatch to Host Physician Career Fair at the Rochester Marriott on May 12, 2015 2Health News:PracticeMatch to Host Physician Career Fair at the Rochester Marriott on May 12, 2015 3Health News:New AIS Newsletter Features Expert Insights and Strategies on Value-Based Care Arrangements 2Health News:Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com 2Health News:Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com 3Health News:BioFit to Introduce New Models from Latest Specialized Ergonomic Seating Lines at NeoCon 2015 2Health News:BioFit to Introduce New Models from Latest Specialized Ergonomic Seating Lines at NeoCon 2015 3
... Christian Medical College (CMC), Vellore, to undertake stem cell research.// ... can be developed into heart muscles, nerve cells and if ... ,"It is a matter of great prestige that the CMC ... far-reaching implications in the lives of people and it is ...
... age had an increased risk of developing high blood ... Johansson, Karolinska Institute, Stockholm reported in the Journal Circulation ... prone to high blood pressure compared to normal born ... data from 329,495 Swedish men born between 1973 and ...
... expert assert that Haj should be called off in case a ... Didier Pittet, director of the Infection Control Programme at Geneva’s University ... creating the conditions in which a pandemic strain of flu could ... Avian flu has affected the Southeast Asian nations ...
... Recent research published in this week’s Australian Medical Journal (AMA) ... face a greater risk of complications if they choose to ... The study has found ... scarring that can cause uterine ruptures during birth, post-partum bleeding, ...
... to ever-changing environments, oxidative stress, and worst of ... against all these insults, gain resistance to new ... genetic information from other better-adapted types of bacteria ... horizontal gene transfer. , According to the ...
... minister of human resources, has been hospitalized after he complained ... of Punjab and Haryana Sunday evening, was admitted to the ... night. ,Though he is still under observation, doctors ... ,Singh was in the city to attend the inauguration ...
Cached Medicine News:Health News:Qualms Of Bird Flu Risk During Haj Pilgrimage 2Health News:Bacteria Evolve Armamentarium Against Antibiotics By ‘Stealing’ Gen 2
... The BD Directigen EZ RSV Test utilizes ... reagent and one device for rapid RSV detection. ... a method whereby dried reagents have already ... reduced to a two-step process, with clear-cut results ...
VIKIA Rota-Adeno is a rapid, qualitative, chromatographic immunoassay which simultaneously detects rotaviruses and adenoviruses in stool specimens. Rotaviruses and adenoviruses are responsible for,th...
The ELISA test is used for detection and semi quantitation of igG antibodies to proteinase 3(PR3) in human sera, as an aid to the diagnosis is of Wegener's granulomatosis....
... Enzyme immunoassay for detection and ... serum.no subjective criteria as in indirect ... quantitative results.Parallel processing with the Anti-MPO-ELISA ... possible; many of the reagents can ...
Medicine Products: